Forest Laboratories, Inc. (FRX) Announces Completion of Acquisition Of Cerexa, Inc.
1/12/2007 8:38:12 AM
More...
|
The Day In Review: Forest Laboratories, Inc. (FRX) Buys Cerexa, Inc. For $480 Million
12/15/2006 12:25:33 PM
More...
|
Cerexa, Inc. Expands Portfolio Of Novel Anti-Infective Therapies Through In-Licensing Agreement With Meiji Seika Kaisha, Ltd.
11/1/2006 12:24:23 PM
More...
|
Cerexa, Inc. Release: Phase 2 Study Shows Ceftaroline Highly Efficacious In Treatment Of cSSSI Compared To Standard Therapy
9/29/2006 2:11:06 PM
More...
|
Cerexa, Inc. Reports Positive Top-Line Results For Phase 2 Clinical Trial Of Ceftaroline
8/2/2006 10:23:45 AM
More...
|
Cerexa, Inc. Appoints George H. Talbot, M.D., Chief Medical Officer, Executive Vice President
7/28/2006 10:39:52 AM
More...
|
Cerexa, Inc. Announces Completion Enrollment In Ceftaroline Phase 2 Trial
4/5/2006 10:24:09 AM
More...
|
FDA Grants Cerexa, Inc. Fast Track Designation For PPI-0903
3/14/2006 10:31:17 AM
More...
|
East Bay Biotechs Hit Sales Block
1/3/2006 11:44:06 AM
More...
|
Cerexa, Inc. To Present At Credit Suisse First Boston Healthcare Conference
11/15/2005 12:19:49 PM
More...
|
|